New obesity drug enters early safety testing
NCT ID NCT07225556
First seen Nov 06, 2025 · Last updated Jun 13, 2026 · Updated 29 times
Summary
This early-stage study tests a new drug called LY4167586 in 84 people with obesity or overweight who are otherwise healthy. The main goal is to check the drug's safety and how the body processes it after a single dose. Participants will be monitored for about 7 months to track any side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fortrea Clinical Research Unit
RECRUITINGMadison, Wisconsin, 53704, United States
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.